(NASDAQ: UPB) Upstream Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.3%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.33%.
Upstream Bio's earnings in 2026 is -$156,764,000.On average, 10 Wall Street analysts forecast UPB's earnings for 2026 to be -$156,158,150, with the lowest UPB earnings forecast at -$179,727,446, and the highest UPB earnings forecast at -$128,567,217. On average, 8 Wall Street analysts forecast UPB's earnings for 2027 to be -$160,419,235, with the lowest UPB earnings forecast at -$207,993,186, and the highest UPB earnings forecast at -$87,425,708.
In 2028, UPB is forecast to generate -$172,587,544 in earnings, with the lowest earnings forecast at -$244,791,981 and the highest earnings forecast at -$78,854,560.